BRAF inhibitor resistance of melanoma cells triggers increased susceptibility to natural killer cell-mediated lysis

BRAF inhibitor resistance of melanoma cells triggers increased susceptibility to natural killer cell-mediated lysis

Background Targeted therapies and immunotherapies are first-line treatments for patients with advanced melanoma. Serine–threonine protein kinase B-RAF (BRAF) and mitogen-activated protein kinase (MEK) inhibition leads to a 70% response rate in patients with advanced melanoma with a BRAFV600E/K mutat...

Full description

Bibliographic Details
Main Authors: Antoine Toubert, Eric Pasmant, Alexandra Frazao, Louise Rethacker, Géraldine Jeudy, Marina Colombo, Marie-Françoise Avril, Helene Moins-Teisserenc, Marie Roelens, Sophie Dalac, Eve Maubec, Anne Caignard
Format: Article
Language:English
Published: BMJ Publishing Group 2020-07-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/8/2/e000275.full

Internet

https://jitc.bmj.com/content/8/2/e000275.full

Similar Items